Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations
Jae Kyeom Sim, Juwhan Choi, Sung Yong Lee
Korean J Intern Med. 2023;38(6):787-796. Published online November 1, 2023
Lung cancer is a dismal disease as a leading cause of overall cancer death, but the development of immune checkpoint inhibitors (ICIs) in driver gene mutation negative metastatic non-small cell lung cancer (NSCLC) is changing the paradigm of lung cancer treatment. Recently, ICIs are expanding their ..
|
|
Hemato-oncology
Geriatric functional assessment for decision-making on adjuvant chemotherapy in older colon cancer patients
Hyun Jin Bang, Hyun Jeong Shim, Ga Ram Kim, Jun Eul Hwang, Woo Kyun Bae, Ik Joo Chung, Sang Hee Cho
Korean J Intern Med. 2022;37(3):660-672. Published online April 15, 2022
Background/Aims: Despite the increasing need for geriatric assessment prior to chemotherapy, the method for this assessment remains inadequate for older cancer patients. We aimed to propose a simple assessment method to predict the performance of adjuvant chemotherapy in older patients after colon c..
|
|
Pulmonology
Clinical efficacy of adjuvant chemotherapy in stage IB (< 4 cm) non-small cell lung cancer patients with high-risk factors
Juwhan Choi, Jee Youn Oh, Young Seok Lee, Kyung Hoon Min, Jae Jeong Shim, Sue In Choi, Dong Won Park, Chan Kwon Park, Eun Joo Kang, Hwan Seok Yong, Bong Kyung Shin, Hyun Koo Kim, Sung Yong Lee
Korean J Intern Med. 2022;37(1):127-136. Published online July 29, 2021
Background/Aims: Adjuvant chemotherapy is the standard of care for resected stage II-IIIA non-small cell lung cancer (NCSLC). The efficacy of adjuvant chemotherapy in stage IB (< 4 cm) NSCLC with high-risk factors is controversial.
Methods: This retrospective multicenter study included 285 stage IB..
|
|
S-1 Monotherapy as a Neoadjuvant Treatment for Locally Advanced Gastric Cancer
Jong Yul Jung, Sun Young Rha, Joong Bae Ahn, Woo Ick Yang, Sung Hoon Noh, Hyun Cheol Chung, Hei-Cheul Jeung
Korean J Intern Med. 2008;23(1):37-41. Published online March 20, 2008
S-1, a novel oral fluoropyrimidine, is an effective therapeutic agent for gastric cancer. Herein, we report a case with locally advanced gastric cancer that achieved a curative resection after S-1 monotherapy as neoadjuvant treatment. A 68-year-old man was diagnosed with gastric cancer and massiv..
|
|
|